December 01, 2009 08:42 ET

MedClean Technologies (OTCBB: MCLN): One Man's Medical Waste Is Another Man's Treasure

LOS ANGELES, CA--(Marketwire - December 1, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on MedClean Technologies (OTCBB: MCLN).

MedClean Technologies engages in the design, sale, installation, and servicing of onsite turnkey systems to treat regulated medical waste. We believe the product is a game changer in the Regulated Medical Waste space and it has already begun saving hospitals and clinics millions of dollars by affecting not only how they handle the often times hazardous waste material, but also in regulatory compliance fees and reporting requirements.

MCLN's stock has just emerged from the sub-penny trading level and our own short-term trading target of $.40 is based on our own in-depth technical, fundamental and financial analysis of the company.

MCLN was recently awarded a substantial MedAssets Supply Chain Systems Contract. Thanks to orders from hospitals and clinics, MCLN's management team has informed us that they are running at full capacity and still experiencing an accumulation of unfilled orders.

MCLN's management team previously worked together at eResearchTechnology, Inc. -- where they helped grow the company's market valuation from $27 million to a peak of $1.5 billion, receiving recognition from Fortune Magazine as the number two fastest growing company in America. They recognized a fantastic new market opportunity with MCLN and are building that vision now.

The complete report is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556